Jpmorgan Chase & CO Cullinan Oncology, Inc. Transaction History

Jpmorgan Chase & CO

  • $1.27 Trillion
  • Q1 2025

A detailed history of Jpmorgan Chase & CO transactions in Cullinan Oncology, Inc. stock. As of the latest transaction made, Jpmorgan Chase & CO holds 43,547 shares of CGEM stock, worth $316,586. This represents 0.0% of its overall portfolio holdings.

Number of Shares
43,547
Previous 198,214 78.03%
Holding current value
$316,586
Previous $2.41 Million 86.37%
% of portfolio
0.0%
Previous 0.0%

Shares

20 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2025

May 12, 2025
SELL
$7.57 - $12.68 $1.17 Million - $1.96 Million
-154,667 Reduced 78.03%
43,547 $329,000
Q4 2024

Feb 12, 2025
BUY
$10.77 - $17.6 $1.82 Million - $2.98 Million
169,104 Added 580.91%
198,214 $2.41 Million
Q3 2024

Dec 26, 2024
BUY
$16.03 - $20.86 $93,647 - $121,864
5,842 Added 25.11%
29,110 $487,000
Q3 2024

Nov 08, 2024
BUY
$16.03 - $20.86 $93,647 - $121,864
5,842 Added 25.11%
29,110 $487,000
Q2 2024

Dec 26, 2024
SELL
$15.63 - $29.35 $91,310 - $171,462
-5,842 Reduced 20.07%
23,268 $405,000
Q2 2024

Aug 12, 2024
BUY
$15.63 - $29.35 $59,362 - $111,471
3,798 Added 19.51%
23,268 $405,000
Q1 2024

Dec 26, 2024
SELL
$10.17 - $19.02 $98,038 - $183,352
-9,640 Reduced 33.12%
19,470 $331,000
Q1 2024

May 10, 2024
SELL
$10.17 - $19.02 $58,202 - $108,851
-5,723 Reduced 22.72%
19,470 $331,000
Q4 2023

Dec 26, 2024
SELL
$7.89 - $10.23 $30,905 - $40,070
-3,917 Reduced 13.46%
25,193 $256,000
Q4 2023

Feb 12, 2024
BUY
$7.89 - $10.23 $6,935 - $8,992
879 Added 3.62%
25,193 $256,000
Q3 2023

Nov 14, 2023
BUY
$9.05 - $11.72 $32,896 - $42,602
3,635 Added 17.58%
24,314 $220,000
Q2 2023

Aug 11, 2023
SELL
$8.8 - $13.4 $13,763 - $20,957
-1,564 Reduced 7.03%
20,679 $222,000
Q1 2023

May 18, 2023
BUY
$10.2 - $11.91 $204,591 - $238,890
20,058 Added 917.99%
22,243 $227,000
Q1 2023

May 11, 2023
SELL
$10.2 - $11.91 $175,440 - $204,852
-17,200 Reduced 88.73%
2,185 $22,000
Q4 2022

Feb 13, 2023
SELL
$9.72 - $13.62 $5,093 - $7,136
-524 Reduced 2.63%
19,385 $205,000
Q3 2022

Nov 14, 2022
BUY
$11.82 - $15.42 $22,623 - $29,513
1,914 Added 10.64%
19,909 $256,000
Q2 2022

Aug 11, 2022
SELL
$7.31 - $13.55 $45,153 - $83,698
-6,177 Reduced 25.55%
17,995 $231,000
Q1 2022

May 11, 2022
BUY
$10.47 - $16.75 $43,084 - $68,926
4,115 Added 20.52%
24,172 $253,000
Q4 2021

Feb 10, 2022
BUY
$15.36 - $25.0 $75,540 - $122,950
4,918 Added 32.49%
20,057 $309,000
Q3 2021

Nov 12, 2021
BUY
$22.56 - $29.68 $341,535 - $449,325
15,139 New
15,139 $341,000

Others Institutions Holding CGEM

# of Institutions
152
Shares Held
68.3M
Call Options Held
15.6K
Put Options Held
17.9K
View Full List

About Cullinan Oncology, Inc.

CGEM Quotes by TradingView
  • Ticker CGEM
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 45,612,200
  • Market Cap $332M
  • Description
  • Cullinan Oncology Inc., a biopharmaceutical company, focuses on developing a pipeline of targeted oncology and immuno-oncology therapies for cancer patients in the United States. The company's lead candidate is the CLN-081, an orally available small molecule that is in a Phase I/IIa dose escalation and expansion trial for treating patients with ...
More about CGEM
Track This Portfolio

Track Jpmorgan Chase & CO Portfolio

Follow Jpmorgan Chase & CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

News

Stay updated on Jpmorgan Chase & CO with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email